Related Experiment Video
Updated: Apr 4, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Novel targeted agents for the treatment of lung cancer in China
Si-Yang Liu1, Tony Mok2, Yi-Long Wu1
1Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Abstract:
Since the discovery of epidermal growth factor receptor mutations and epidermal growth factor receptor tyrosine kinase inhibitors, lung cancer treatment in China has entered the precision era. However, novel targeted agents based on novel biomarkers still need to be developed. In the current study, the authors review the biomarker features of lung cancer in the Chinese population and the novel agents that are aimed at novel targets. Furthermore, they discuss issues that require improvement for the production of novel drugs and provided future directions for development in China.
Insights
Lung cancer treatment in China is now personalized, but new targeted therapies and biomarkers are needed. This review examines Chinese lung cancer biomarkers and novel agents, discussing future development directions.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Lung cancer treatment in China has advanced to a precision medicine era.
- The advent of epidermal growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) has revolutionized treatment.
- However, there remains a need for novel targeted agents and biomarkers.
Purpose of the Study:
- To review biomarker features specific to lung cancer in the Chinese population.
- To identify and discuss novel targeted agents for emerging biomarkers.
- To explore challenges and future directions for novel drug development in China.
Main Methods:
- Literature review of biomarker characteristics in Chinese lung cancer patients.
- Analysis of current and emerging novel targeted agents.
- Discussion of drug development hurdles and strategic pathways.
Main Results:
- The Chinese population exhibits distinct lung cancer biomarker profiles.
- Several novel targeted agents are in development for these specific biomarkers.
- Key areas for improvement in drug production and regulatory processes were identified.
Conclusions:
- Personalized medicine for lung cancer in China requires continuous innovation in targeted therapies.
- Further research into population-specific biomarkers is crucial.
- Addressing drug development challenges will accelerate the availability of novel treatments for Chinese lung cancer patients.
More Related Videos
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...